Pierre Marquet

List of Publications by Citations

213 papers	6,870 citations	48 h-index	71 g-index
234 ext. papers	8,020 ext. citations	4.3 avg, IF	5.64 L-index

#	Paper	IF	Citations
213	Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. *Therapeutic Drug Monitoring*, **2009**, 31, 139-52	3.2	347
212	Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. *Drug Metabolism and Disposition*, **2005**, 33, 139-46	4	226
211	Mechanisms underlying postmortem redistribution of drugs: a review. *Journal of Analytical Toxicology*, **2003**, 27, 533-44	2.9	199
210	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. *Therapeutic Drug Monitoring*, **2019**, 41, 261-307	3.2	163
209	CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. *Clinical Pharmacology and Therapeutics*, **2004**, 75, 422-33	6.1	150
208	Screening of drugs and toxic compounds with liquid chromatography-linear ion trap tandem mass spectrometry. *Clinical Chemistry*, **2006**, 52, 1735-42	5.5	119
207	Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. *Journal of Antimicrobial Chemotherapy*, **2010**, 65, 2628-40	5.1	113
206	In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. *Drug Metabolism and Disposition*, **2005**, 33, 689-95	4	112
205	Progress of liquid chromatography-mass spectrometry in clinical and forensic toxicology. *Therapeutic Drug Monitoring*, **2002**, 24, 255-76	3.2	105
204	Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. *Clinical Pharmacokinetics*, **2009**, 48, 805-16	6.2	103
203	Current role of LC-MS in therapeutic drug monitoring. *Analytical and Bioanalytical Chemistry*, **2007**, 388, 1327-49	4.4	92
202	Pitfalls and prevention strategies for liquid chromatography-tandem mass spectrometry in the selected reaction-monitoring mode for drug analysis. *Clinical Chemistry*, **2008**, 54, 1519-27	5.5	91
201	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. *Transplantation Reviews*, **2011**, 25, 47-57	3.3	89
200	Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients. *Clinical Pharmacokinetics*, **2004**, 43, 253-66	6.2	88
199	Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. *Therapeutic Drug Monitoring*, **2005**, 27, 354-61	3.2	84
198	Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. *Fundamental and Clinical Pharmacology*, **2002**, 16, 253-62	3.1	83
197	LC-MS/MS systematic toxicological analysis: comparison of MS/MS spectra obtained with different instruments and settings. *Clinical Biochemistry*, **2005**, 38, 362-72	3.5	81

196	Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf. *British Journal of Clinical Pharmacology*, **2011**, 71, 391-402	3.8	79
195	Pesticide contamination of workers in vineyards in France. *Journal of Exposure Science and Environmental Epidemiology*, **2006**, 16, 115-24	6.7	77
194	CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. *Clinical Pharmacology and Therapeutics*, **2006**, 80, 51-60	6.1	76
193	Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. *Drug Metabolism and Disposition*, **2010**, 38, 40-5	4	75
192	Applications of liquid chromatography--mass spectrometry in analytical toxicology: a review. *Journal of Analytical Toxicology*, **1997**, 21, 116-26	2.9	75
191	Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. *Hepatology*, **2008**, 47, 1453-61	11.2	75
190	Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. *Therapeutic Drug Monitoring*, **2004**, 26, 609-19	3.2	73
189	Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. *Clinical Pharmacokinetics*, **2010**, 49, 683-92	6.2	71
188	Therapeutic Drug Monitoring of Everolimus: A Consensus Report. *Therapeutic Drug Monitoring*, **2016**, 38, 143-69	3.2	71
187	Evaluation of an improved general unknown screening procedure using liquid chromatography-electrospray-mass spectrometry by comparison with gas chromatography and high-performance liquid-chromatography--diode array detection. *Journal of the American Society for Mass Spectrometry*, **2003**, 14, 14-22	3.5	70
186	Buprenorphine withdrawal syndrome in a newborn. *Clinical Pharmacology and Therapeutics*, **1997**, 62, 569-71	6.1	68
185	Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee. *Therapeutic Drug Monitoring*, **2016**, 38, 170-89	3.2	65
184	Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. *European Journal of Clinical Pharmacology*, **2002**, 57, 805-11	2.8	64
183	Sensitive and specific multiresidue methods for the determination of pesticides of various classes in clinical and forensic toxicology. *Forensic Science International*, **2001**, 121, 116-25	2.6	62
182	Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. *Arthritis and Rheumatism*, **2010**, 62, 2047-54		61
181	Is LC-MS suitable for a comprehensive screening of drugs and poisons in clinical toxicology?. *Therapeutic Drug Monitoring*, **2002**, 24, 125-33	3.2	60
180	Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. *Pharmacogenetics and Genomics*, **2007**, 17, 321-30	1.9	59
179	Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse. *Drug Metabolism and Disposition*, **2013**, 41, 568-74	4	58

178	Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. *Therapeutic Drug Monitoring*, **2004**, 26, 600-8	3.2	58
177	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. *Therapeutic Drug Monitoring*, **2016**, 38 Suppl 1, S1-20	3.2	57
176	Determination of buprenorphine and norbuprenorphine in whole blood by liquid chromatography-mass spectrometry. *Journal of Analytical Toxicology*, **1997**, 21, 160-5	2.9	56
175	Liquid chromatography-tandem mass spectrometry for detection of low concentrations of 21 benzodiazepines, metabolites, and analogs in urine: method with forensic applications. *Clinical Chemistry*, **2006**, 52, 1346-55	5.5	56
174	CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. *Transplantation*, **2011**, 91, 652-6	1.8	53
173	A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. *Clinical Pharmacokinetics*, **2005**, 44, 837-47	6.2	53
172	Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. *Clinical Pharmacokinetics*, **2006**, 45, 1135-48	6.2	53
171	Uterus retrieval process from brain dead donors. *Fertility and Sterility*, **2014**, 102, 476-82	4.8	50
170	HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. *Liver International*, **2015**, 35, 2222-7	7.9	49
169	Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. *Clinical Pharmacokinetics*, **2012**, 51, 175-86	6.2	49
168	Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. *Clinical Pharmacokinetics*, **2002**, 41, 71-80	6.2	49
167	Establishing Biomarkers in Transplant Medicine: A Critical Review of Current Approaches. *Transplantation*, **2016**, 100, 2024-38	1.8	49
166	Application of a gamma model of absorption to oral cyclosporin. *Clinical Pharmacokinetics*, **2001**, 40, 375-82	6.2	48
165	Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. *Clinical Pharmacokinetics*, **2009**, 48, 745-58	6.2	46
164	Adaptive control methods for the dose individualisation of anticancer agents. *Clinical Pharmacokinetics*, **2000**, 38, 315-53	6.2	43
163	Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. *Pharmacogenetics and Genomics*, **2010**, 20, 537-43	1.9	42
162	Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. *Clinical Pharmacokinetics*, **2005**, 44, 1317-28	6.2	42
161	A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. *British Journal of Clinical Pharmacology*, **2006**, 62, 477-84	3.8	42

160	Relationship between psychotropic drugs and thyroid function: a review. *Toxicology and Applied Pharmacology*, **1998**, 149, 127-35	4.6	41
159	Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. *Therapeutic Drug Monitoring*, **2013**, 35, 322-7	3.2	40
158	General unknown screening procedure for the characterization of human drug metabolites in forensic toxicology: applications and constraints. *Journal of Separation Science*, **2009**, 32, 3074-83	3.4	40
157	Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs. *Therapeutic Drug Monitoring*, **2016**, 38 Suppl 1, S57-69	3.2	39
156	Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I. *Clinical Pharmacokinetics*, **2009**, 48, 419-62	6.2	39
155	Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry. *Therapeutic Drug Monitoring*, **2006**, 28, 274-7	3.2	39
154	Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. *Therapeutic Drug Monitoring*, **2010**, 32, 129-35	3.2	39
153	Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. *Drug Metabolism and Disposition*, **2007**, 35, 350-5	4	38
152	Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome. *Pharmacological Research*, **2011**, 63, 423-31	10.2	37
151	Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. *British Journal of Clinical Pharmacology*, **2010**, 69, 675-83	3.8	36
150	Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. *Clinical Pharmacokinetics*, **2008**, 47, 277-84	6.2	36
149	Impact of Laboratory Practices on Interlaboratory Variability in Therapeutic Drug Monitoring of Immunosuppressive Drugs. *Therapeutic Drug Monitoring*, **2015**, 37, 718-24	3.2	35
148	Screening of pesticides in blood with liquid chromatography-linear ion trap mass spectrometry. *Analytical and Bioanalytical Chemistry*, **2010**, 396, 2235-49	4.4	35
147	Ribavirin: Past, present and future. *World Journal of Hepatology*, **2016**, 8, 123-30	3.4	35
146	QuEChERS sample preparation prior to LC-MS/MS determination of opiates, amphetamines, and cocaine metabolites in whole blood. *Analytical and Bioanalytical Chemistry*, **2016**, 408, 1467-74	4.4	34
145	Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients. *Therapeutic Drug Monitoring*, **2011**, 33, 285-94	3.2	34
144	Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. *American Journal of Transplantation*, **2005**, 5, 1477-82	8.7	33
143	Analytical findings in a suicide involving sodium azide. *Journal of Analytical Toxicology*, **1996**, 20, 134-8	2.9	33

142	In silico pharmacology: Drug membrane partitioning and crossing. *Pharmacological Research*, **2016**, 111, 471-486	10.2	33
141	Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study. *Journal of Steroid Biochemistry and Molecular Biology*, **2017**, 169, 210-218	5.1	32
140	Development and validation of a peripheral blood mRNA assay for the assessment of antibody-mediated kidney allograft rejection: A multicentre, prospective study. *EBioMedicine*, **2019**, 46, 463-472	8.8	31
139	Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma. *Clinical Pharmacokinetics*, **2002**, 41, 1095-104	6.2	30
138	A Non-fatal Case of Intoxication with Foxglove, Documented by Means of Liquid Chromatography-Electrospray-Mass Spectrometry. *Journal of Forensic Sciences*, **2000**, 45, 14845J	1.8	30
137	Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. *Frontiers in Pharmacology*, **2017**, 8, 358	5.6	29
136	Rheumatoid factor interference in a tacrolimus immunoassay. *Therapeutic Drug Monitoring*, **2009**, 31, 743-5	3.2	29
135	Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. *Clinical Pharmacology and Therapeutics*, **2005**, 78, 34-42	6.1	29
134	The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. *Expert Opinion on Drug Metabolism and Toxicology*, **2011**, 7, 731-43	5.5	28
133	Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II. *Clinical Pharmacokinetics*, **2009**, 48, 489-516	6.2	28
132	Population Pharmacokinetics and Bayesian Estimators for Refined Dose Adjustment of a New Tacrolimus Formulation in Kidney and Liver Transplant Patients. *Clinical Pharmacokinetics*, **2017**, 56, 1491-1498	6.2	27
131	Uterus tolerance to extended cold ischemic storage after auto-transplantation in ewes. *European Journal of Obstetrics, Gynecology and Reproductive Biology*, **2017**, 214, 162-167	2.4	27
130	Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring. *British Journal of Clinical Pharmacology*, **2014**, 78, 867-76	3.8	27
129	Falsely elevated whole-blood tacrolimus concentrations in a kidney-transplant patient: potential hazards. *Transplant International*, **2010**, 23, 227-30	3	27
128	Effect of mycophenolate acyl-glucuronide on human recombinant type 2 inosine monophosphate dehydrogenase. *Clinical Chemistry*, **2009**, 55, 986-93	5.5	27
127	Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. *Clinical Pharmacokinetics*, **2006**, 45, 905-22	6.2	27
126	Post-mortem redistribution of three beta-blockers in the rabbit. *International Journal of Legal Medicine*, **2006**, 120, 226-32	3.1	27
125	Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. *Pharmacogenomics*, **2015**, 16, 1119-34	2.6	26

124	Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation. *Clinical Pharmacokinetics*, **2009**, 48, 667-75	6.2	26
123	Multicenter evaluation of a new inosine monophosphate dehydrogenase inhibition assay for quantification of total mycophenolic acid in plasma. *Therapeutic Drug Monitoring*, **2008**, 30, 428-33	3.2	26
122	Advagraf( ) , a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts. *Transplant International*, **2016**, 29, 860-9	3	25
121	Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus. *Fundamental and Clinical Pharmacology*, **2012**, 26, 463-72	3.1	25
120	Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients. *Clinical Chemistry*, **2013**, 59, 1761-9	5.5	25
119	Simultaneous determination of amphetamine and its analogs in human whole blood by gas chromatography-mass spectrometry. *Biomedical Applications*, **1997**, 700, 77-82		25
118	Multisite analytical evaluation of the Abbott ARCHITECT cyclosporine assay. *Therapeutic Drug Monitoring*, **2010**, 32, 145-51	3.2	25
117	Identification and quantitation of six non-depolarizing neuromuscular blocking agents by LC-MS in biological fluids. *Journal of Analytical Toxicology*, **2004**, 28, 105-10	2.9	24
116	Tungsten Determination in Biological Fluids, Hair and Nails by Plasma Emission Spectrometry in a Case of Severe Acute Intoxication in Man. *Journal of Forensic Sciences*, **1997**, 42, 14162J	1.8	24
115	Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. *Pharmacogenetics and Genomics*, **2014**, 24, 256-62	1.9	23
114	Determination of LSD and N-demethyl-LSD in urine by liquid chromatography coupled to electrospray ionization mass spectrometry. *Biomedical Applications*, **1997**, 692, 329-35		23
113	Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinants. *Pharmacological Research*, **2011**, 63, 1-7	10.2	22
112	A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. *Nephrology Dialysis Transplantation*, **2010**, 25, 3096-106	4.3	22
111	Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions. *Transplantation*, **2003**, 76, 683-8	1.8	22
110	Determination of three beta-blockers in biofluids and solid tissues by liquid chromatography-electrospray-mass spectrometry. *Journal of Analytical Toxicology*, **2004**, 28, 674-9	2.9	22
109	Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship. *Pharmacological Research*, **2017**, 121, 138-144	10.2	21
108	Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients. *Clinical Pharmacokinetics*, **2012**, 51, 29-39	6.2	21
107	Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. *Xenobiotica*, **2011**, 41, 752-7	2	21

106	Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients. *Pharmacogenetics and Genomics*, **2012**, 22, 725-32	1.9	21
105	Endogenous Metabolites-Mediated Communication Between OAT1/OAT3 and OATP1B1 May Explain the Association Between SLCO1B1 SNPs and Methotrexate Toxicity. *Clinical Pharmacology and Therapeutics*, **2018**, 104, 687-698	6.1	20
104	Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome. *Clinical Journal of the American Society of Nephrology: CJASN*, **2016**, 11, 1777-1782	6.9	20
103	Identification of acepromazine in hair: an illustration of the difficulties encountered in investigating drug-facilitated crimes. *Journal of Forensic Sciences*, **2008**, 53, 755-9	1.8	20
102	New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs. *Pharmacogenomics*, **2016**, 17, 277-96	2.6	19
101	Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients. *Transplantation*, **2016**, 100, 2129-2137	1.8	18
100	Inhibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships. *Pharmacological Research*, **2011**, 63, 432-8	10.2	18
99	Development and evaluation of a simulation procedure to take into account various assays for the Bayesian dose adjustment of tacrolimus. *Therapeutic Drug Monitoring*, **2011**, 33, 171-7	3.2	18
98	Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation. *Transplantation*, **2016**, 100, 640-7	1.8	18
97	Simultaneous evaluation of six human glucuronidation activities in liver microsomes using liquid chromatography-tandem mass spectrometry. *Analytical Biochemistry*, **2012**, 427, 52-9	3.1	17
96	Low alfentanil target-concentrations improve hemodynamic and intubating conditions during induction with sevoflurane. *Canadian Journal of Anaesthesia*, **2004**, 51, 382-7	3	17
95	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. *Therapeutic Drug Monitoring*, **2021**, 43, 150-200	3.2	17
94	Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients. *Pharmacological Research*, **2018**, 129, 84-94	10.2	17
93	Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 484-9	5.1	16
92	LC-MS vs. GC-MS, online extraction systems, advantages of technology for drug screening assays. *Methods in Molecular Biology*, **2012**, 902, 15-27	1.4	16
91	Pharmacokinetic Therapeutic Drug Monitoring of Advagraf in More Than 500 Adult Renal Transplant Patients, Using an Expert System Online. *Therapeutic Drug Monitoring*, **2018**, 40, 285-291	3.2	15
90	Tacrolimus pharmacodynamics and pharmacogenetics along the calcineurin pathway in human lymphocytes. *Clinical Chemistry*, **2014**, 60, 1336-45	5.5	15
89	Feasibility of ribavirin therapeutic drug monitoring in hepatitis C. *Therapeutic Drug Monitoring*, **2009**, 31, 374-81	3.2	15

88	Clinical application of population pharmacokinetic methods developed for immunosuppressive drugs. *Therapeutic Drug Monitoring*, **2005**, 27, 727-32	3.2	15
87	Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients. *Pharmacological Research*, **2015**, 99, 308-15	10.2	14
86	Calcineurin activity assay measurement by liquid chromatography-tandem mass spectrometry in the multiple reaction monitoring mode. *Clinical Chemistry*, **2014**, 60, 353-60	5.5	14
85	General unknown screening procedure for the characterization of human drug metabolites: Application to loratadine phase I metabolism. *Journal of Separation Science*, **2009**, 32, 2209-17	3.4	14
84	The Key Role of Warm and Cold Ischemia in Uterus Transplantation: A Review. *Journal of Clinical Medicine*, **2019**, 8,	5.1	13
83	Ciclosporin population pharmacokinetics and Bayesian estimation in thoracic transplant recipients. *Clinical Pharmacokinetics*, **2013**, 52, 277-88	6.2	13
82	Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients. *British Journal of Clinical Pharmacology*, **2014**, 78, 836-46	3.8	13
81	Mapping cyclosporine-induced changes in protein secretion by renal cells using stable isotope labeling with amino acids in cell culture (SILAC). *Journal of Proteomics*, **2012**, 75, 3674-87	3.9	13
80	Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment. *Digestive and Liver Disease*, **2011**, 43, 850-5	3.3	13
79	Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: A model-based meta-analysis approach. *British Journal of Clinical Pharmacology*, **2019**, 85, 2793-2823	3.8	12
78	How to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigation. *Pharmacological Research*, **2015**, 100, 281-7	10.2	12
77	Ischemia/reperfusion-associated tubular cells injury in renal transplantation: Can metabolomics inform about mechanisms and help identify new therapeutic targets?. *Pharmacological Research*, **2018**, 129, 34-43	10.2	12
76	A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation. *Pharmacogenomics*, **2016**, 17, 375-91	2.6	12
75	Fully automated sample preparation procedure to measure drugs of abuse in plasma by liquid chromatography tandem mass spectrometry. *Analytical and Bioanalytical Chemistry*, **2018**, 410, 5071-5085	4.4	12
74	Calcineurin regulation of cytoskeleton organization: a new paradigm to analyse the effects of calcineurin inhibitors on the kidney. *Journal of Cellular and Molecular Medicine*, **2012**, 16, 218-27	5.6	12
73	Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients. *Pharmacological Research*, **2010**, 61, 167-74	10.2	12
72	Cost-effectiveness analysis of individualized mycophenolate mofetil dosing in kidney transplant patients in the APOMYGRE trial. *Transplantation*, **2010**, 89, 1255-62	1.8	12
71	Anti-hepatitis C virus drugs and kidney. *World Journal of Hepatology*, **2016**, 8, 1343-1353	3.4	12

70	Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. *Pharmacological Research*, **2016**, 111, 501-508	10.2	12
69	Population pharmacokinetic model and Bayesian estimator for 2 tacrolimus formulations in adult liver transplant patients. *British Journal of Clinical Pharmacology*, **2019**, 85, 1740-1750	3.8	11
68	Performance of the new mycophenolate assay based on IMPDH enzymatic activity for pharmacokinetic investigations and setup of Bayesian estimators in different populations of allograft recipients. *Therapeutic Drug Monitoring*, **2009**, 31, 443-50	3.2	11
67	Ingestion of high-dose buprenorphine by a 4 year-old child. *Journal of Toxicology: Clinical Toxicology* , **2004**, 42, 993-5		11
66	Analytical Aspects of Volatile Substance Abuse (VSA). *Journal of Forensic Sciences*, **2003**, 48, 2002376	1.8	11
65	Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study. *Transplantation*, **2016**, 100, 1705-13	1.8	11
64	Adherence profiles in kidney transplant patients: Causes and consequences. *Patient Education and Counseling*, **2020**, 103, 189-198	3.1	11
63	An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies. *PLoS ONE*, **2017**, 12, e0180236	3.7	10
62	Counterpoint: Is pharmacokinetic or pharmacodynamic monitoring of calcineurin inhibition therapy necessary?. *Clinical Chemistry*, **2010**, 56, 736-9	5.5	9
61	Influence of sampling-time error on cyclosporine measurements nominally at 2 hours after administration. *Clinical Chemistry*, **2003**, 49, 813-5	5.5	9
60	Stability of ribavirin concentrations depending on the type of blood collection tube and preanalytical conditions. *Therapeutic Drug Monitoring*, **2010**, 32, 237-41	3.2	9
59	A donor and recipient candidate gene association study of allograft loss in renal transplant recipients receiving a tacrolimus-based regimen. *American Journal of Transplantation*, **2018**, 18, 2905-2913	8.7	8
58	A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators. *Clinical Pharmacokinetics*, **2018**, 57, 1459-1469	6.2	8
57	An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine. *Toxicology and Applied Pharmacology*, **2002**, 183, 189-97	4.6	8
56	Thyroid accumulation and adverse effects of imipramine and desipramine in rats after long-term administration. *Pharmacology*, **1998**, 57, 242-8	2.3	8
55	A Time-Dependent Model Describes Methotrexate Elimination and Supports Dynamic Modification of MRP2/ABCC2 Activity. *Therapeutic Drug Monitoring*, **2017**, 39, 145-156	3.2	7
54	The European Association for Clinical Pharmacology and Therapeutics-25 years young and going strong. *European Journal of Clinical Pharmacology*, **2019**, 75, 743-750	2.8	7
53	Liquid chromatography tandem mass spectrometry quantitation of intracellular concentrations of ganciclovir and its phosphorylated forms. *Analytical and Bioanalytical Chemistry*, **2015**, 407, 3449-56	4.4	7

52	Ribavirin therapeutic drug monitoring: why, when and how?. *Fundamental and Clinical Pharmacology*, **2010**, 24, 401-6	3.1	7
51	ESI-MS-MS library of 1,253 compounds for application in forensic and clinical toxicology. *Analytical and Bioanalytical Chemistry*, **2010**, 396, 1947	4.4	7
50	Effects of Ischemia-Reperfusion on Tubular Cell Membrane Transporters and Consequences in Kidney Transplantation. *Journal of Clinical Medicine*, **2020**, 9,	5.1	7
49	Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. *Medicine (United States)*, **2017**, 96, e6469	1.8	6
48	Translational research: precision medicine, personalized medicine, targeted therapies: marketing or science?. *Therapie*, **2015**, 70, 1-19	3.8	6
47	In vitro study of mycophenolic acid glucuronidation. *Drug Metabolism and Disposition*, **2004**, 32, 1524; author reply 1525	4	6
46	Pharmacology of High-Dose Buprenorphine01-12		6
45	Tacrolimus Exposure Prediction Using Machine Learning. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 361-369	6.1	6
44	Activity of the Calcineurin Pathway in Patients on the Liver Transplantation Waiting List: Factors of Variability and Response to Tacrolimus Inhibition. *Clinical Chemistry*, **2017**, 63, 1734-1744	5.5	5
43	Enteric-coated mycophenolate sodium in de novo pediatric renal transplant patients. *Pediatric Nephrology*, **2009**, 24, 395-402	3.2	5
42	Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses. *Therapeutic Drug Monitoring*, **2009**, 31, 451-6	3.2	5
41	Case Study of Neonates Born to Mothers Undergoing Buprenorphine Maintenance Treatment125-136		5
40	Mycophenolic Acid Exposure Prediction Using Machine Learning. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 370-379	6.1	5
39	Pharmacodynamic Monitoring of mTOR Inhibitors. *Therapeutic Drug Monitoring*, **2019**, 41, 160-167	3.2	5
38	Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patients. *British Journal of Clinical Pharmacology*, **2020**, 86, 1550-1559	3.8	4
37	Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study. *BMC Cancer*, **2017**, 17, 901	4.8	4
36	Overview of accessibility and quality of antiepileptic drugs in Madagascar. *Seizure: the Journal of the British Epilepsy Association*, **2016**, 41, 134-40	3.2	4
35	Comment on "Population Pharmacokinetics of Mycophenolic Acid: An Update". *Clinical Pharmacokinetics*, **2018**, 57, 1211-1213	6.2	4

34	Metabolic alterations of uterine grafts after extended cold ischemic storage: experimental study in ewes. *Molecular Human Reproduction*, **2019**, 25, 647-659	4.4	4
33	Acylglucuronide in alkaline conditions: migration vs. hydrolysis. *Journal of Molecular Modeling*, **2013**, 19, 2423-32	2	4
32	Consensus conference on a composite endpoint for clinical trials on immunosuppressive drugs in lung transplantation. *Transplantation*, **2014**, 98, 1331-8	1.8	4
31	Integrative Omics Analysis Unravels Microvascular Inflammation-Related Pathways in Kidney Allograft Biopsies. *Frontiers in Immunology*, **2021**, 12, 738795	8.4	4
30	Immunosuppressant quantification in intravenous microdialysate towards novel quasi-continuous therapeutic drug monitoring in transplanted patients. *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, 935-945	5.9	4
29	Pharmacokinetics, Pharmacodynamics, and Therapeutic Drug Monitoring of Valganciclovir and Ganciclovir in Transplantation. *Clinical Pharmacology and Therapeutics*, **2021**,	6.1	4
28	Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0. *Fundamental and Clinical Pharmacology*, **2006**, 20, 91-6	3.1	3
27	Fatal Intoxications with Chloral Hydrate. *Journal of Forensic Sciences*, **2001**, 46, 15181J	1.8	3
26	Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: The example of tacrolimus. *Pharmacological Research*, **2021**, 167, 105578	10.2	3
25	Thoroughly Validated Bayesian Estimator and Limited Sampling Strategy for Dose Individualization of Ganciclovir and Valganciclovir in Pediatric Transplant Recipients. *Clinical Pharmacokinetics*, **2021**, 60, 1449-1462	6.2	3
24	Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients. *British Journal of Clinical Pharmacology*, **2021**, 87, 3105-3114	3.8	3
23	Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin. *Therapeutic Drug Monitoring*, **2016**, 38, 684-692	3.2	2
22	Pelvic magnetic resonance imaging in the ewe: a model for experimental gynecologic research. *Journal of Obstetrics and Gynaecology Research*, **2014**, 40, 133-8	1.9	2
21	Pretransplantation calcineurin activity: towards individualized therapy?. *Liver International*, **2009**, 29, 1454-6	7.9	2
20	Modelling ciclosporin double-peak absorption profiles in the early post-transplantation period. *Clinical Pharmacokinetics*, **2004**, 43, 1055-7	6.2	2
19	Clinical Pharmacokinetics and Bayesian Estimators for the Individual Dose Adjustment of a Generic Formulation of Tacrolimus in Adult Kidney Transplant Recipients. *Clinical Pharmacokinetics*, **2021**, 60, 611-622	6.2	2
18	A Machine Learning Approach to Estimate the Glomerular Filtration Rate in Intensive Care Unit Patients Based on Plasma Iohexol Concentrations and Covariates. *Clinical Pharmacokinetics*, **2021**, 60, 223-233	6.2	2
17	Untargeted Screening of Urinary Peptides Using Offline Nano-Liquid Chromatography: MALDI-TOF/TOF Mass Spectrometry. *Methods in Molecular Biology*, **2018**, 1788, 113-121	1.4	1

16	Evaluation of Experiences with Immunosuppressive Drugs in Transplantation: Validation of the MESI Scale in French. *Pharmaceutical Medicine*, **2017**, 31, 455-465	2.3	1
15	Comparison of Tacrolimus Starting Doses Based on CYP3A5 Phenotype or Genotype in Kidney Transplant Recipients. *Progress in Transplantation*, **2019**, 29, 300-308	1.1	1
14	LC-MS/MS screen for xenobiotics and metabolites. *Methods in Molecular Biology*, **2012**, 902, 129-38	1.4	1
13	Untargeted screening of urinary peptides with liquid chromatography coupled to hybrid linear-ion trap tandem mass spectrometry. *Journal of Chromatography A*, **2012**, 1259, 138-47	4.5	1
12	Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. *Therapeutic Drug Monitoring*, **2006**, 28, 138; author reply 139	3.2	1
11	The apoptosis-inducing toxin brefeldin A is taken up and secondarily released by neurons. *Neuroscience Research Communications*, **2000**, 27, 125-133		1
10	Uterus human leucocyte antigen expression in the perspective of transplantation. *Journal of Obstetrics and Gynaecology Research*, **2016**, 42, 1789-1795	1.9	1
9	First-Line Toxicological Screening with Fully Automated Extraction. *Journal of Analytical Toxicology*, **2021**, 45, 252-268	2.9	1
8	Tacrolimus Bayesian Dose Adjustment in Pediatric Renal Transplant Recipients. *Therapeutic Drug Monitoring*, **2021**, 43, 472-480	3.2	1
7	Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial.. *Transplantation Direct*, **2022**, 8, e1316	2.3	1
6	Towards therapeutic drug monitoring of mycophenolic acid in mucous membrane pemphigoid: A retrospective single-centre study. *Fundamental and Clinical Pharmacology*, **2021**, 35, 1179-1187	3.1	0
5	A Machine Learning Approach to Predict Interdose Vancomycin Exposure.. *Pharmaceutical Research* , **2022**, 39, 721	4.5	0
4	Reply:. *Hepatology*, **2008**, 48, 693-694	11.2	
3	How has the future investment program stimulated research and innovation in health?. *Therapie*, **2022**, 77, 19-19	3.8	
2	Pharmacogenomics of Immunosuppressants70-97		
1	Professor Folke Sjövist peacefully passed away on March 30, 2020. *European Journal of Clinical Pharmacology*, **2020**, 76, 1477-1478	2.8	